[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-448015-105":59,"doc-detail-448015-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","association-of-venous-thromboembolism-risk-with-atopic-dermatitis-and-janus-kinase-inhibitors-treatment-a-mendelian-randomization-study","Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment - A Mendelian Randomization Study","","Observational research reports conflicting findings on the risk of venous thromboembolism (VTE) in patients with atopic dermatitis (AD), particularly when treated with Janus kinase inhibitors (JAKi), while causal links remain uncertain. A two-sample Mendelian randomization framework tested whether genetic susceptibility to AD and JAKi target genes (JAK1, JAK2, JAK3, TYK2) affects VTE, deep vein thrombosis (DVT) and pulmonary embolism (PE). No significant causal effects were detected across outcomes; robustness was evaluated via pleiotropy and heterogeneity tests.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/association-of-venous-thromboembolism-risk-with-atopic-dermatitis-and-janus-kinase-inhibitors-treatment-a-mendelian-randomization-study/448015/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/association-of-venous-thromboembolism-risk-with-atopic-dermatitis-and-janus-kinase-inhibitors-treatment-a-mendelian-randomization-study/448015.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-06","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study investigate about atopic dermatitis and VTE?","Question",{"text":112,"@type":113},"It evaluates whether genetic susceptibility to atopic dermatitis causally influences the risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were causal effects tested in this research?",{"text":117,"@type":113},"The study used two-sample Mendelian randomization with genome-wide association study summary statistics and eQTLGen data, applying inverse variance weighting with a random-effects method plus robustness checks for pleiotropy and heterogeneity.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding AD and VTE risk?",{"text":121,"@type":113},"The Mendelian randomization results showed no significant causal effects of AD on VTE, DVT, or PE, with odds ratios close to 1 and non-significant P values.",{"name":123,"@type":110,"acceptedAnswer":124},"What do the results imply for prescribing Janus kinase inhibitors to patients with AD?",{"text":125,"@type":113},"The analysis found no genetic causal associations between JAKi target genes (JAK1, JAK2, JAK3, TYK2) and VTE outcomes, which the authors suggest may support clinical decision-making when prescribing JAKi for AD patients.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},448015,1790995036,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":46},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study  \nZhiqiang Chen, MS 1,*, Shuaibo Wang2,*, and Yifei Wang, PhD3   \nClinical and Applied Thrombosis/Hemostasis Volume 32: 1-8 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/10760296251413253](DOI: 10.1177/10760296251413253)[ ](DOI: 10.1177/10760296251413253)[journals.sagepub.com/home/cat](journals.sagepub.com/home/cat)  \nAbstract  \nBackground: The risk of venous thromboembolism (VTE) among patients with atopic dermatitis (AD), especially when receiving treatment with Janus kinase inhibitors (JAKi), has been reported in observational studies. however, the causal relationships between them remain unclear. We aim to explore the causal effects of AD and JAKi on VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE).  \nMethods: Two-sample Mendelian randomization (MR) analyses were conducted to examine the causal between genetic susceptibility to AD or JAKi target genes (including JAK1, JAK2, JAK3 and tyrosine kinase 2 [TYK2]) and VTE (encompassing DVT and PE) using summary statistics from genome-wide association studies and eQTLGen project. Inverse variance weighting with random effect method was used as the main analytic approach. Pleiotropy and heterogeneity tests were conducted to assess the robustness of the findings.  \nResults: No significant causal effects were found between AD and the risk of (odds ratio [OR]: 0.97, 95% confidence interval [CI]: 0.91-1.03, P = .352), DVT (OR: 0.99, 95% CI: 0.89-1.10, P = .789), and PE (OR: 1.06, 95% CI: 0.93-1.20, P = .387). Similarly, there was no causal association between the expression of JAK1, JAK2, JAK3 or TYK2 and VTE, DVT and PE.  \nConclusion: The MR analysis revealed no genetic causal relationships between either AD or JAKi target genes and VTE. These findings may provide a reference for clinicians in prescribing JAKi for patients with AD.  \nKeywords  \natopic dermatitis, Janus kinase inhibitors, venous thromboembolism, Mendelian randomization  \nReceived: August 13, 2025; revised: November 24, 2025; accepted: December 17, 2025  \nSummary Table  \nWhat is known about this topic?  \n• The association between atopic dermatitis (AD) and venous thromboembolism (VTE) was conflicting according to available research studies.  \n• Evidence from observational studies regarding the association between Janus kinase inhibitors (JAKi) and VTE also remains controversial.  \nWhat does this paper add?  \n1 Department of Vascular Surgery, the Fuyang Affiliated Hospital of Anhui Medical University, Fuyang, China  \n2College of Clinical Medicine, North Henan Medical University, Xinxiang, China  \n3Department of Dermatology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China  \n*These authors contributed equally to this work.  \nCorresponding author:  \nYifei Wang, Department of Dermatology, The First Affiliated Hospital of Bengbu Medical University, No. 287 Changhuai Road, Longzihu District, Bengbu 233004, Anhui, China.  \nEmail: [husterwyf@163.com](husterwyf@163.com)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ([https://creativecommons.org/l](https://creativecommons.org/l)icenses/by-nc/4.0/) which permits non-commercial use,  \nreproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)).  \n• There were no significant causal effects of AD on VTE.  \n• No significant causal effects of JAKi target genes on VTE were also observed.  \n• These findings may provide a reference for clinicians in prescribing JAKi for patients with AD.  \nIntro","cbCaifoZGIzjq7Iq","https://ap.wps.com/l/cbCaifoZGIzjq7Iq","pdf",714880,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Summary Table\n## What is known about this topic?\n## What does this paper add?\n# Introduction","[{\"question\":\"What question does the study investigate about atopic dermatitis and VTE?\",\"answer\":\"It evaluates whether genetic susceptibility to atopic dermatitis causally influences the risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism.\"},{\"question\":\"How were causal effects tested in this research?\",\"answer\":\"The study used two-sample Mendelian randomization with genome-wide association study summary statistics and eQTLGen data, applying inverse variance weighting with a random-effects method plus robustness checks for pleiotropy and heterogeneity.\"},{\"question\":\"What were the main findings regarding AD and VTE risk?\",\"answer\":\"The Mendelian randomization results showed no significant causal effects of AD on VTE, DVT, or PE, with odds ratios close to 1 and non-significant P values.\"},{\"question\":\"What do the results imply for prescribing Janus kinase inhibitors to patients with AD?\",\"answer\":\"The analysis found no genetic causal associations between JAKi target genes (JAK1, JAK2, JAK3, TYK2) and VTE outcomes, which the authors suggest may support clinical decision-making when prescribing JAKi for AD patients.\"}]","Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment - A Mendelian Randomization Study | PDF",1790724710]